Other
DO THE BENEFITS OF ASPIRIN EXCEED THE RISK OF MAJOR BLEEDS IN PATIENTS TREATED FOR PRIMARY PREVENTION OF CEREBROVASCULAR AND CARDIOVASCULAR DISEASE?
PETAR KES
orcid.org/0000-0002-4501-4823
; University of Zagreb, School of Medicine and Academy of Medical Sciences of Croatia, Zagreb, Croatia
VANJA BAŠIĆ KES
; Sestre milosrdnice University Hospital Centre, University of Zagreb, School of Dental Medicine, Department of Neurology, Zagreb and Josip Juraj Strossmayer University in Osijek, Faculty of Medicine, Department of Neurology, Osijek, Croatia
Abstract
Daily aspirin use has long been heralded for its cardioprotective effects, particularly in at-risk individuals like those with diabetes mellitus. However, a signifi cant amount of research published in the last 5 years has called into question the benefits of aspirin for primary prevention of cardiovascular disease. Risk factors for gastrointestinal bleeding with aspirin use include higher dose and longer duration of use, history of gastrointestinal ulcers or upper gastrointestinal pain, bleeding disorders, renal failure, severe liver disease, and thrombocytopenia. Other factors that increase the risk of gastrointestinal or intracranial bleeding with low-dose aspirin use include concurrent anticoagulation or nonsteroidal anti-infl ammatory drug use, uncontrolled hypertension, male sex, and older age. Aspirin for primary cardiovascular disease prevention should be highly individualized, based on the benefi t-risk ratio assessment for the given patient.
Keywords
aspirin; bleeding; cardiovascular disease; cerebrovascular disease; primary prevention; secondary prevention
Hrčak ID:
218968
URI
Publication date:
4.4.2019.
Visits: 927 *